MA45245A - Méthode de traitement de maladie intestinale inflammatoire - Google Patents
Méthode de traitement de maladie intestinale inflammatoireInfo
- Publication number
- MA45245A MA45245A MA045245A MA45245A MA45245A MA 45245 A MA45245 A MA 45245A MA 045245 A MA045245 A MA 045245A MA 45245 A MA45245 A MA 45245A MA 45245 A MA45245 A MA 45245A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- intestinal disease
- inflammatory intestinal
- inflammatory
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662349026P | 2016-06-12 | 2016-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45245A true MA45245A (fr) | 2019-04-17 |
Family
ID=59270123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045245A MA45245A (fr) | 2016-06-12 | 2017-06-12 | Méthode de traitement de maladie intestinale inflammatoire |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11389533B2 (fr) |
| EP (1) | EP3468597A1 (fr) |
| JP (1) | JP7202893B2 (fr) |
| CN (1) | CN109414502A (fr) |
| CA (1) | CA3027286A1 (fr) |
| MA (1) | MA45245A (fr) |
| WO (1) | WO2017218434A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3581585A1 (fr) | 2014-11-26 | 2019-12-18 | Millennium Pharmaceuticals, Inc. | Vedolizumab pour le traitement de la fistulisation de la maladie de crohn |
| CA3223332A1 (fr) * | 2021-06-17 | 2022-12-22 | Prometheus Laboratories Inc. | Systemes et methodes de therapie ciblee amelioree |
| WO2024249568A1 (fr) * | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Compositions d'anticorps anti-intégrine alpha4beta7 et procédés d'utilisation |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | ドメイン‐変性不変部を有する抗体 |
| EP0714409A1 (fr) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Anticorps |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| ES2290955T3 (es) | 1995-02-10 | 2008-02-16 | Millennium Pharmaceuticals, Inc. | Adresinas vasculares de mucosas y sus usos. |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US6197582B1 (en) | 1998-03-18 | 2001-03-06 | The Trustees Of Columbia University In The City Of New York | Development of human monoclonal antibodies and uses thereof |
| US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| WO2002078779A1 (fr) | 2001-03-27 | 2002-10-10 | Zeon Corporation | Fil-guide medical |
| PL2990422T3 (pl) | 2004-09-03 | 2018-11-30 | Genentech, Inc. | Humanizowani antagoniści anty-beta7 i ich zastosowania |
| US20070122404A1 (en) | 2005-11-17 | 2007-05-31 | O'keefe Theresa L | Humanized immunoglobulin reactive with alpha4beta7 integrin |
| EA034783B1 (ru) | 2009-03-20 | 2020-03-20 | Эмджен Инк. | Антитело-антагонист, специфичное для гетеродимера альфа4бета7 |
| TWI698254B (zh) | 2011-05-02 | 2020-07-11 | 美商千禧製藥公司 | 抗-α4β7抗體之調配物 |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| EP3581585A1 (fr) | 2014-11-26 | 2019-12-18 | Millennium Pharmaceuticals, Inc. | Vedolizumab pour le traitement de la fistulisation de la maladie de crohn |
| US20170360926A1 (en) | 2014-12-24 | 2017-12-21 | Millennium Pharmaceuticals, Inc. | PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-alpha4beta7 INTEGRIN ANTIBODY |
| MA41636A (fr) | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
| PE20180509A1 (es) | 2015-06-08 | 2018-03-09 | Univ Washington | Composiciones y metodos para tratar la enfermedad celiaca |
| IL261750B2 (en) | 2016-03-14 | 2024-07-01 | Millennium Pharm Inc | Method of preventing graft versus host disease |
| EP3430053A1 (fr) | 2016-03-14 | 2019-01-23 | Millennium Pharmaceuticals, Inc. | Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte |
| US11760803B2 (en) | 2016-03-24 | 2023-09-19 | Takeda Pharmaceutical Company Limited | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
| TW201735949A (zh) | 2016-03-24 | 2017-10-16 | 千禧製藥公司 | 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法 |
| US10918716B2 (en) | 2016-05-04 | 2021-02-16 | Millennium Pharmaceuticals, Inc. | Triple combination therapy for treating Crohn's disease |
-
2017
- 2017-06-12 MA MA045245A patent/MA45245A/fr unknown
- 2017-06-12 CN CN201780041382.4A patent/CN109414502A/zh active Pending
- 2017-06-12 CA CA3027286A patent/CA3027286A1/fr active Pending
- 2017-06-12 US US16/309,002 patent/US11389533B2/en active Active
- 2017-06-12 JP JP2018564829A patent/JP7202893B2/ja active Active
- 2017-06-12 EP EP17734895.0A patent/EP3468597A1/fr active Pending
- 2017-06-12 WO PCT/US2017/037072 patent/WO2017218434A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11389533B2 (en) | 2022-07-19 |
| US20190255172A1 (en) | 2019-08-22 |
| JP2019519544A (ja) | 2019-07-11 |
| WO2017218434A1 (fr) | 2017-12-21 |
| CA3027286A1 (fr) | 2017-12-21 |
| EP3468597A1 (fr) | 2019-04-17 |
| CN109414502A (zh) | 2019-03-01 |
| JP7202893B2 (ja) | 2023-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46771A (fr) | Méthode de traitement de tumeur immunothérapeutique | |
| EP3380121A4 (fr) | Méthode de traitement de troubles oculaires | |
| EP3488001A4 (fr) | Traitement du cancer | |
| EP3463350A4 (fr) | Méthode de traitement de la fibrose hépatique | |
| EP3341080A4 (fr) | Méthode de traitement du cancer | |
| EP2971127A4 (fr) | Procédés de diagnostic et de traitement de maladie intestinale inflammatoire | |
| MA46954A (fr) | Méthodes de traitement d'états inflammatoires | |
| EP3288383A4 (fr) | Méthodes de traitement du cancer | |
| EP3291815A4 (fr) | Méthodes de traitement d'une maladie neurodégénérative | |
| HK1252037A1 (zh) | 治療炎性疾病的方法 | |
| EP3658139A4 (fr) | Méthodes de traitement de maladies hépatiques | |
| MA41115A (fr) | Procédé de traitement de la maladie d'alzheimer | |
| EP3375440A4 (fr) | Méthode de traitement de la mucosite | |
| EP3294345A4 (fr) | Formulations de tpp1 et méthodes de traitement de la maladie cln2 | |
| MA41462A (fr) | Méthode de traitement de maladies | |
| MA48862A (fr) | Méthode de traitement de tumeur immunothérapeutique | |
| EP3389634A4 (fr) | Méthodes de traitement du cancer | |
| EP3405203A4 (fr) | Méthodes de traitement du cancer | |
| MA45149A (fr) | Méthodes de traitement de la maladie d'alzheimer | |
| MA46061A (fr) | Traitement ascaroside de maladies auto-immunes et inflammatoires | |
| EP3630101A4 (fr) | Méthodes de traitement de maladies | |
| SMT201800690T1 (it) | Trattamento di malattie colestatiche intraepatiche | |
| EP3389652A4 (fr) | Méthodes de traitement du cancer | |
| IL257764B (en) | Methods for treatment of diseases | |
| EP3618640A4 (fr) | Méthode de traitement de troubles du tube digestif |